Global Colon Screening Market Size To Exceed USD 26.85 Billion by 2033: Market Growth Report

Global Colon Screening Market Size To Exceed USD 26.85 Billion by 2033

According to a research report published by Spherical Insights & Consulting, The Global Colon Screening Market Size is Expected to Grow from USD 16.38 Billion in 2023 to USD 26.85 Billion by 2033, at a CAGR of 5.07% during the forecast period 2023-2033.  

The global colon screening market refers to the industry that focuses on the creation, manufacturing, and dissemination of diagnostic tools and technology for the early detection of colon-related illnesses like colorectal cancer. Further, to improve patient outcomes through early diagnosis, it comprises diagnostic procedures that include colonoscopies, fecal testing, and imaging modalities. Key driving factors for the growth of the colon screening market include the rising incidences of colorectal cancer, aging populations worldwide, government screening programs, and growing awareness of the advantages of early detection. Technological developments in non-invasive testing, including DNA-based screenings and fecal immunochemical assays (FIT), increase demand and improve the effectiveness and accessibility of early diagnosis in several organizations. However, lack of expertise, high expenses of complex procedures, restricted availability in low-income areas, and patient resistance because of discomfort or concern about invasive screening techniques.

The test segment accounted for the largest revenue share in 2023 and is projected to grow at a significant CAGR during the forecast period.

On the basis of type, the global colon screening market is divided into test and product. Among these, the test segment accounted for the largest revenue share in 2023 and is projected to grow at a significant CAGR during the forecast period. The segment growth is attributed to blood-based screening tests, including Shield from Guardant Health, which has FDA approval, and has become increasingly prevalent. They provide a non-invasive, accurate, and convenient alternative that encourages early detection and increased patient compliance.

The colonoscopes segment accounted for the highest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.

On the basis of product, the global colon screening market is divided into colonoscopes, sigmoidoscopes, CT scanners, and MRI. Among these, the colonoscopes segment accounted for the highest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. The segment growth is driven because of modern innovations, including PillBot, which provides non-invasive, high-resolution imaging for precise diagnosis, enhancing patient comfort and outcomes while increasing the use of individualized, tech-driven colon screening alternatives.

North America is anticipated to hold the largest share of the global colon screening market over the predicted timeframe.

North America is anticipated to hold the largest share of the global colon screening market over the predicted timeframe. The regional market growth can be attributed because of strong governmental and private healthcare programs, an established healthcare infrastructure, high awareness levels, and broad access to innovative diagnostic equipment.

Asia Pacific is expected to grow at the fastest CAGR in the global colon screening market during the forecast period. The regional market growth is driven because to increased government attempts, increased public awareness, and focused screening programs like Malaysia's NSPCRC, which prioritize iFOBT-based early diagnosis and attempt to enhance outcomes from therapy across the region.

Company Profiling

Major vendors in the global colon screening market are Olympus Corporation, PENTAX Medical (Hoya Corporation), FUJIFILM Holdings Corporation, Medtronic, Ambu A/S, Baxter (Hillrom & Welch Allyn), EndoFresh, Daichuan Medical, Bracco, Varay Laborix, and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In March 2025, New Day Diagnostics officially launched ColoHealth nationwide, expanding access to colorectal cancer screening through a blood-based test. This innovative screening method detects methylated Septin9 DNA, a biomarker associated with colorectal cancer, offering a simple blood draw procedure that enhances patient convenience and participation.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global colon screening market based on the below-mentioned segments: 

Global Colon Screening Market, By Type

• Test
• Product

Global Colon Screening Market, By Product

• Colonoscopes
• Sigmoidoscopes
• CT Scanners
• MRI

Global Colon Screening Market, Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa